Lyell Immunopharma, Inc.LYELNASDAQ
Loading
Operating Cash Flow Growth AcceleratingAccelerating
Percentile Rank83
Studio
Year-over-Year Change

Year-over-year operating cash flow growth rate

Percentile
P83
Within normal range
vs 2Y Ago
2.2x
Strong expansion
Streak
1 yr
Consecutive growthAccelerating
PeriodValue
20257.62%
20240.79%
20233.46%
2022-34.30%
202121.52%
2020-507.54%
20190.00%